The recently published paper on the Asian subgroup analysis in the EMPA-REG OUTCOME^® trial (Circ J 81:227-234, 2017). This paper shows that the reductions in CV outcomes and CV mortality with empagliflozin in Asian patients with T2DM and established CV disease were consistent with the overall EMPA-REG OUTCOME^® trial population.

Read full Text